Salwan Al Mutar, MD
Medical Oncology · Dallas, TXNPI 1508285313
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $825 of the $1,046 with a category attached, or 78.9%. Partner Therapeutics, Inc. accounts for 78.9% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 6 payments — averaging $174.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Partner Therapeutics, Inc.$825
- Ipsen Biopharmaceuticals, Inc$140
- Tempus AI, Inc$81
Across 32 payments — averaging $3800.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$61K
- AstraZeneca$36K
- Incyte Corporation$12K
- Bristol Myers Squibb$8K
- Astellas Pharma Global Development$5K
What the payments were for
- Consulting fees$82579%
- Food & beverage$818%
- Education$14013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Partner Therapeutics, Inc. | 1 | $825 |
| Ipsen Biopharmaceuticals, Inc | 2 | $140 |
| Tempus AI, Inc | 3 | $81 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bizengri$825
How this compares
$1,046 in reported general payments places this provider in the 25th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 106 | $363,783 |
| LynparzaOlaparib | 13 | $223,912 |
| Everolimus | 14 | $152,609 |
| Imatinib Mesylate | 12 | $25,261 |
| EliquisApixaban | 28 | $17,759 |
| XareltoRivaroxaban | 20 | $13,999 |
| Prochlorperazine Maleate | 137 | $1,336 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 37 | $1,018 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 28 | $884 |
| Dexamethasone | 104 | $853 |
| Ondansetron Hcl | 106 | $850 |
| LoperamideLoperamide Hcl | 53 | $759 |
| Olanzapine | 14 | $635 |
| Oxycodone Hcl | 21 | $479 |
| Potassium Chloride | 19 | $466 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.